Hepatitis C virus inhibitors

摘要

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:;
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

主权项

1. A compound represented by Formula (Vd), or (Ve):wherein:
L1, L3, L4 and L6 at each occurrence are each independently absent or a linear aliphatic group wherein at least one of L1 and L3 is present and wherein at least one of L4 and L6 is present; L2 is selected from absent, aryl, heteroaryl, heterocyclic, C3-C8 cycloalkyl, and C3-C8 cycloalkenyl, each optionally substituted; R6 is C1-C8 alkyl optionally substituted with amino, halogen, hydroxy, protected amino, or O(C1-C4 alkyl); U at each occurrence is independently CH2, CHF, CHMe, CF2, C═CH2, C═CF2, or C(R7)2, wherein R7 is hydrogen, halogen, optionally substituted C1-C4 cycloalkyl, or optionally substituted C3-C8 cycloalkyl; alternatively, the two geminal R7 groups are taken together with the carbon to which they are attached to form a spiro, optionally substituted C3-C7 cycloalkyl or optionally substituted 3- to 7-membered heterocyclic; R7a is hydrogen; and R7b is hydrogen, methyl or optionally substituted C3-C8 cycloalkyl; or alternatively R7a and U or U and R7b are taken together with the carbon atoms to which they are attached to form a fused, optionally substituted C3-C8 cycloalkyl, and the other of R7b or R7a is hydrogen; or yet alternatively, U, R7a and R7b are taken together with the carbon atoms to which they are attached to form a bridged, optionally substituted C4-C7 cycloalkyl; or a pharmaceutically acceptable salt thereof.